SARS‐CoV‐2 spike protein acts as a β‐adrenergic receptor agonist: A potential mechanism for cardiac sequelae of long COVID
Journal of Internal Medicine · 2024
DOI: 10.1111/joim.20000 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Internal Medicine, 2024. Verfasst von Xiangning Deng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
Background
Currently, pathophysiological mechanisms of post‐acute sequelae of coronavirus disease‐19‐cardiovascular syndrome (PASC‐CVS) remain unknown. Methods and results Patients with PASC‐CVS exhibited significantly higher circulating levels of severe acute respiratory syndrome‐coronavirus‐2 spike protein S1 than the non‐PASC‐CVS patients and healthy controls. Moreover, individuals with high plasma spike protein S1 concentrations exhibited elevated heart rates and normalized low frequency, suggesting cardiac β‐adrenergic receptor (β‐AR) hyperactivity. Microscale thermophoresis (MST) assay revealed that the spike protein bound to β 1 ‐ and β 2 ‐AR, but not to D1‐dopamine receptor. These interactions were blocked by β 1 ‐ and β 2 ‐AR blockers. Molecular docking and MST assay of β‐AR mutants revealed that the spike protein interacted with the extracellular loop 2 of both β‐ARs. In cardiomyocytes, spike protein dose‐dependently increased the cyclic adenosine monophosphate production with or without epinephrine, indicating its allosteric effects on β‐ARs.
Conclusion
Severe acute respiratory syndrome‐coronavirus‐2 spike proteins act as an allosteric β‐AR agonist, leading to cardiac β‐AR hyperactivity, thus contributing to PASC‐CVS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China.
- State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China.
- Haihe Laboratory of Cell Ecosystem, Beijing, China.
- Research Unit of Medical Science Research Management/Basic and Clinical Research of Metabolic Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China.
- Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing, China.
- Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
ORCID-Profile: Han Xiao
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- CAMS Innovation Fund for Medical Sciences
- Haihe Laboratory of Cell Ecosystem Innovation Fund
Zitieren
APA
Deng, X., Cui, H., Liang, H., Wang, X., Yu, H., Wang, J., Wang, W., Liu, D., Zhang, Y., Dong, E., Tang, Y., & Xiao, H. (2024). SARS‐CoV‐2 spike protein acts as a β‐adrenergic receptor agonist: A potential mechanism for cardiac sequelae of long COVID. Journal of Internal Medicine. https://doi.org/10.1111/joim.20000
Vancouver
Deng X, Cui H, Liang H, Wang X, Yu H, Wang J, et al. SARS‐CoV‐2 spike protein acts as a β‐adrenergic receptor agonist: A potential mechanism for cardiac sequelae of long COVID. Journal of Internal Medicine. 2024. doi:10.1111/joim.20000
BibTeX
@article{Deng2024,
author = {Deng, Xiangning and Cui, Hongtu and Liang, Hao and Wang, Xinyu and Yu, Haiyi and Wang, Jingjia and Wang, Wenyao and Liu, Dongyang and Zhang, Youyi and Dong, Erdan and Tang, Yida and Xiao, Han},
title = {SARS‐CoV‐2 spike protein acts as a β‐adrenergic receptor agonist: A potential mechanism for cardiac sequelae of long COVID},
journal = {Journal of Internal Medicine},
year = {2024},
doi = {10.1111/joim.20000}
}
EUVIMED